IPO
Maze Therapeutics Files Plans for Proposed IPO
The firm, which plans to use the ticker symbol "MAZE" on the Nasdaq, develops drugs designed to mimic the protective effects of certain genetic variants.
The firm has submitted its xR assay to the FDA and is prioritizing its entry into the minimal residual disease space.
Tempus AI Prices $410.7M Initial Public Offering
The oncology data company priced its initial public offering of 11.1 million shares at $37.00 per share.
Boundless Bio Prices $100M Initial Public Offering
The firm will use the proceeds to advance its two clinical candidates targeting ecDNA and to fund development of its diagnostic and a third ecDNA drug program.
Kyverna Therapeutics, Autoimmune Disease CAR T-Cell Therapy Developer, Files to Go Public
Kyverna's lead candidate is an autologous cell therapy being studied in refractory lupus nephritis and other rheumatology and neurology indications.
Sep 20, 2023
RayzeBio Raises $358M in Initial Public Offering
Oct 27, 2022
Jul 14, 2022
South Korean Biotech Lunit Prices $28M IPO
Oct 8, 2021